Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Agfa-Gevaert NV is a Belgian-German multinational corporation specializing in imaging technology and IT solutions, with over 150 years of history since its origins in dye and photographic materials manufacturing. Headquartered in Mortsel, Belgium, the company develops, manufactures, and distributes analogue and digital imaging systems, software, and related products primarily for the healthcare, printing, and industrial sectors. Its key divisions include Radiology Solutions, offering X-ray films, digital radiography equipment, and image processing software like MUSICA; HealthCare IT, providing enterprise imaging platforms, hospital information systems such as ORBIS, and integrated care solutions; and Digital Print & Chemicals, supplying wide-format inkjet printers, inks, workflow software, printing plates, and innovative ZIRFON membranes for green hydrogen production. Agfa-Gevaert NV employs around 4,765 people globally, operates manufacturing facilities in nine countries, and maintains sales organizations in 40 countries, underscoring its established role in advancing digital transformation and specialized imaging applications across diverse markets.
€0.43
€0.01 (-1.15%)
Live · 04:41 PM · Twelve Data
Operating margin is thin at 0.74%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue declined 4.6% YoY. The question is whether this is cyclical or a structural shift.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€1.08B
▼ -4.6% YoY
Net Income (TTM)
-€62M
▲ +22.8% YoY
Op. Margin
-2.78%
▼ -0.2pp YoY
ROIC
1.40%
▼ -0.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
€13M
▲ +159.2% YoY
Op. Cash Flow (TTM)
€121M
▲ +447.1% YoY
Net Debt
€78M
Cash & Equiv.
€91M
3Y CAGR: -1.7%
Continue Research
Agfa-Gevaert NV (AGFB.XBRU) trades below a two-stage DCF intrinsic value of about €0.98 per share, so at €0.43 the stock looks undervalued (128.9% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Agfa-Gevaert NV scores 45/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about €0.98 per share for AGFB.XBRU, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around €0.74. At today's €0.43, that puts the stock about 128.9% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Agfa-Gevaert NV scores 45 out of 100 on Intrinsiqq's quality score, passing 3 of 6 checks, which makes it a mixed business on these measures. Recent fundamentals include a -2.8% operating margin and a 1.4% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. AGFB.XBRU currently trades below its estimated intrinsic value and scores 45/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.